Clarity Pharma, a UK headquartered distribution partner to mid-market pharmaceutical companies around the world, has announced that a March 2021 audit saw Unit 1 of its warehousing infrastructure achieve Medical Healthcare Regulatory Agency (MHRA) licence approval. The accreditation is in compliance with the new Medical Device Regulations, which came into place in May 2020, and complements the company’s existing licence for its Unit 3 facility.
Clarity Pharma holds an MHRA wholesale dealer licence (H) for the storage and distribution of POM and GSL healthcare products. This state-of-the-art third party logistics warehouse opened its doors in March 2019 providing a purpose-built pharmaceutical distribution facility including dedicated chilled and controlled drugs storage areas, with benchmark safety and security measures in place.
The warehouse is designed to support the company’s market position offering multi-channel pharmaceutical and medical device sales and distribution capabilities, as well as comprehensive regulatory and pharmaceutical consulting services, to partners seeking access to the UK healthcare market. It places the company in an optimal position to offer convenient distribution in the UK, being strategically located outside London Stansted Airport near the M11 corridor with ease of access to both land and air transport.
Mark Simpson, GM and RP Distribution and Quality Services at Clarity Pharma, said: “The inspector was very impressed with our facilities across key criteria including build quality, hygiene and safety standards, and importantly, our people and organisation. The team has worked incredibly hard to bring this best-in-class facility to fruition and we’re proud that the business is now in a great position to support our existing and new customers with excellence in distribution and logistics.”
To discover more about Clarity Pharma, please visit www.clarity-pharma.com